Proleukin interleukin

Interleukin 2 (Aldesleukin, Proleukin ) is a major growth factor and activator of cytotoxic and other T-lymphocytes. It is applied in the therapy of metastas-ing renal carcinoma and melanoma. Side effects include... [Pg.411]

Proleukin Aldesleukin (interleukin 2) Chiron Renal cell carcinoma, metastatic melanoma... [Pg.694]

The bacterium Escherichia coli is preferred for the production of small, aglycosy-lated proteins like Insulin, Proleukin (interleukin-2), Kineret (interleukin-1 recep-... [Pg.267]

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. [Pg.160]

C. Interleukins aldesleukin (interleukin-2, IL-2, Proleukin) Cellular growth factors... [Pg.639]

Interferons and cytokines Aldesleukin, human recombinant interleukin-2, produced Proleukin Lyophilized, 22 X 10 lU vial, reconstitute and use within 48 h IM... [Pg.461]

Aldesleukin. IL-2, aldesleukin. Proleukin. Teceleukin, interleukin-2. IL-2. T-ccll growth factor, in the human form is produced in mature T lymphocytes. Cleavage of the 20-amino acid signal sequence then results in an active protein... [Pg.441]

Adriamycin - doxorubicin Gleevec- imatinib Proleukin - interleukin-2... [Pg.395]

Denmark interleukin-2 protein Proleukin Macrolin Recombinant human IL-2 with N-terminal Ala and Cys 125 mutated to Ser, expressed in E. coli Anti-cancer... [Pg.469]

Interleukin-1 Receptor Antagonist (Antril) USA4 Interleukin-2, Aldesleuk (Proleukin), USA4, 1989 Interleukin-3, IL-3 USA4 ... [Pg.691]

Interleukin-2 Human recombinant lL-2 aldesleukin, proleukin des-alanyl-1, serine-125 human lL-2) differs from native lL-2 in that it is not glycosylated, has no amino terminal Ala, and has an Ser substituted for the Cys at amino acid 125. The potency of the preparation is represented in International Units in a lymphocyte proliferation assay such that 1.1 mg of recombinant lL-2 protein equals 18 million International Units. Aldesleukin has the following in vitro biologic activities of native lL-2 enhancement of lymphocyte proliferation and growth of lL-2-dependent cell lines enhancement of lymphocyte-mediated cytotoxicity and killer cell activity and induction of interferon-7 activity. In vivo administration of aldesleukin in animals produces multiple immunologic effects in a dose-dependent manner. Cellular immunity is profoundly activated with lymphocytosis, eosinophilia, thrombocytopenia, and release of multiple cytokines e.g., TNF-a, lL-1, interferon-7). Aldesleukin is indicated for the treatment of adults with metastatic renal cell carcinoma and melanoma. Administration of aldesleukin has been associated with serious cardiovascular toxicity resulting from capillary leak syndrome, which involves loss of vascular tone and leak of plasma proteins and fluid into the extravascular space. Hypotension, reduced organ perfusion, and death may occur. An increased risk of disseminated infection due to impaired neutrophil function also has been associated with aldesleukin treatment. [Pg.921]

Human interleukin-2 Proleukin , Chiron Therapeutics Metastatic renal cell carcinoma... [Pg.4]

Aldesleukin interleukin-2 (Proleukin) 15.3 1.42 Intermittent IV infusion (1.0) Metastatic renal cell carcinoma, metastatic melanoma Q i Q O O 7 3 2-... [Pg.346]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...